Int J Med Sci 2020; 17(7):892-902. doi:10.7150/ijms.43079


Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges

Haiyan Zeng1,2, Lei Li2, Zhouhua Hou1, Yapeng Zhang2, Zhongxiang Tang2, Shuiping Liu1,2 Corresponding address

1. Department of Infectious Disease, Xiangya Hospital, Central South University, Changsha 410008, China
2. Department of Microbiology, School of Basic Medical Science, Central South University, Changsha 410078, China

This is an open access article distributed under the terms of the Creative Commons Attribution License ( See for full terms and conditions.
Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int J Med Sci 2020; 17(7):892-902. doi:10.7150/ijms.43079. Available from

File import instruction


Owing to the rapid development and wide clinical application of direct acting antiviral (DAA) drugs in the treatment of hepatitis C virus (HCV) infection, the era of interferon-based therapy has almost come to an end. Cumulative studies show that DAA therapy renders high cure efficiency (>90%) and good safety profile, and may even bring some unexpected benefits to the patients. However, some issues of concern arise, one of which is the resistance mutation of HCV genome leading to failure of treatment. With the aim of providing some meaningful references for the treatment of chronic hepatitis C (CHC), this article summarizes the research progress on benefits of DAA accompanied by viral clearance in the treatment of chronic hepatitis and the drug resistance.

Keywords: hepatitis C virus (HCV), direct acting antiviral (DAA), sustained virological response (SVR), resistance-associated substitutions (RAS)


Hepatitis C virus (HCV) infection is a global epidemic. According to the World Health Organization (WHO), approximately 71 million people are currently living with hepatitis C virus worldwide, which is the main cause of chronic hepatitis. The number of death from hepatitis C-related liver disease has exceeded 399 000 yearly [1]. Nowadays, it is well recognized that chronic hepatitis C (CHC) is a major public health problem that can contribute to liver fibrosis, progressive decline in liver function, and ultimately death in patients [1, 2].

As an infectious agent with high sequence variations, HCV is classified into seven genotypes (GT) and is further subdivided into nearly 100 subtypes to date. It is recognized that HCV genotypes have a regionally distinct global distribution: HCV GT1 (46.2%) and 3 (30.1%) dominate the global infections; GT 2, 4, and 6 are responsible for approximately 22.8% of HCV infections; GT 5 accounts for the remaining less than 1%; GT 7 has been identified so far in very few patients originating from Central Africa [3].

In the past two decades, the only standard treatment for patients with HCV infection is peg-interferon plus ribavirin (PegIFN/RBV) in 24 to 72 weeks, but only a limited proportion of patients can achieve a sustained virological response (SVR), defined as HCV RNA continues to be undetectable in serum at 12 weeks after completing treatment. What is worse, the interferon-based agent can cause many adverse effects in more than 10% of patients during and after the treatment [4], such as depression, cytoreduction and hemolytic anemia [5]. Fortunately, as DAA drugs have been developed rapidly and used in the clinical application, the cure rate of chronic hepatitis C has a revolutionary improvement even in patients with liver cirrhosis, and the efficiency persists to rise from the first generation to the third generation DAA drugs [6].

In general, DAAs can be divided into three major classes based on their targets in HCV proteins: the nonstructural protein 3/4A (NS3/4A) protease inhibitors (PIs) that can inhibit HCV polyprotein processing; NS5A inhibitors, inhibiting viral replication and assembly; and NS5B polymerase inhibitors that can block HCV RNA replication [7]. Specifically, each class of DAA includes several different clinical drugs, and nowadays two or three DAA combination therapies are recommended and clinically adopted.

Moreover, DAA combination therapies can achieve high SVR regardless of the HCV GTs and subtypes, even in patients with compensatory cirrhosis and decompensated liver disease.

Surprisingly, numerous studies have shown that DAA can not only effectively and safely remove HCV, but also achieve some unexpected benefits when compared with interferon-based therapy, such as repairing liver function damage, recovery of metabolic impairment and restoration of immunity dysfunction , etc. caused by HCV infection, and the number of patients with adverse effects are much lower. However, despite the excellent antiviral potency and good compatibility of DAA therapy, the consequent challenges such as the association between DAA regimen and tumor genesis [8, 9], and drug resistance which is the main leading factor to the failure of DAA treatments have already attracted the attention of many researchers. Therefore, this article focuses on the research progress of the extra performances of DAA and its drug resistance.

Liver Function Repair

In HCV-infected people, only a minority of those can spontaneously recover from HCV infection, relying on their strong immunity. More than 70% of people will gradually develop chronic hepatitis C virus infection, and a considerable proportion of patients eventually develop into liver fibrosis, cirrhosis, etc. [10-12].

Liver function of more than two-thirds of patients will be damaged by HCV infection. Clinically, chronic HCV infection will contribute to obvious change of some related parameters: high concentration of transaminases (alanine aminotransferase and aspartate aminotransferase), elevated bilirubin concentration, elevated serum globulin concentration, albumin concentration, and lower platelet count. In addition, liver stiffness values and Child-Pugh grading standards can be used to measure the severity of the related liver disease. These data have a positive or negative correlation with the severity of liver function damage.

In recent years, mounting clinical trials have manifested that successful DAA treatment can not only effectively remove HCV, but simultaneously repair liver function damage due to HCV infection in at least two-thirds of the patients [13]. It appears that the parameters related to liver function damage gradually approach the normal interval at the end of treatment and after a long period of time. For example, Edoardo G. Giannini et al. have observed significant change of related parameters, which demonstrated improvement of liver function in a prospective study. In the study, they observed the evidently dropped aminotransferases (P < 0.0001), a progressive increase in serum albumin (P = 0.010), and a decrease in serum bilirubin (P = 0.011) as well as in gamma globulin (P = 0.0003) between baseline level and that after treatment [14]. A similar change was observed in other studies related to DAA and liver function repair [15, 16], which confirms this tendency.

Particularly, there are some studies that have evaluated global prognostic scores for patients with decompensated liver disease, such as the end-stage liver disease model (MELD), showing that the liver function of about 50% of patients has been improved after HCV was removed by DAA. Additionally, these improvements of liver function have been made in the short term [13, 17]. At the same time, some studies have also shown that portal hypertension has also improved in subjects with successful DAA therapy, which has gradually become an independent predictor of hepatocellular carcinoma [13]. Therefore, to some extent, DAA treatment can greatly reduce the incidence and relapse of hepatocellular carcinoma [18, 19].

Interestingly, with respect to patients who were diagnosed as liver fibrosis and cirrhosis, R. Flisiak et al. found that their liver function improvement after DAA treatment was often better than that of non-cirrhotic patients [15]. The success of DAA treatment can reduce the liver stiffness value, which means the regression of fibrosis, the down-regulation of inflammatory activity and the improvement of blood circulation and the regression of hepatic steatosis [20]. In another study, Edoardo G. Giannini et al. also revealed that at least 85% of patients with cirrhosis had a decrease in liver stiffness that dropped by about 40%. However, there were still 10% of patients who had liver stiffness values enhanced, although the virus has been eradicated after DAA treatment [17].

In view that most of these conclusions are based on the fact that the patient is mono-infected with HCV, we wonder whether the DAA treatment has the same effect of clearing HCV and repairing liver function damage for human immunodeficiency virus (HIV)/HCV co-infected patients, because it is well accepted that the HIV/HCV co-infection greatly increases the risk of developing advanced liver disease [21-23], and accelerates liver fibrosis in patients with chronic hepatitis C[24].First of all, Cure rates of over 90%, similar to those in HCV mono-infected patients, can now be achieved in HIV/HCV co-infected patients. This has been documented in clinical trials [25-27] as well as in real-life cohorts [28-30]. Furthermore, there are also studies showing that DAA therapies can achieves liver function repair in patients with co-infection. For instance, a study by Juan Macías et al. demonstrated that DAA treatment also improved liver function impairment in co-infected patients, and the degree of improvement in liver function was similar to that of patients with HCV mono-infection [31]. After multivariate analysis, they showed that only baseline levels of serum albumin and overall deterioration of liver function are independently associated in HIV/HCV co-infected patients; in other words, there is no significant correlation between the status of HIV and the damage and repair of liver function. Consequently, it was concluded that patients with successful DAA treatment, regardless of whether HIV/HCV co-infection or HCV mono-infection, can obtain similar recovery of liver function.

Recovery of Metabolic Damage

The association between HCV infection and dysregulation of metabolic processes has been observed since long ago. Furthermore, chronic HCV infection exerts a significant impact on the development of heart disease and stroke [32]. Increasing epidemiological studies have long demonstrated that the prevalence of type 2 diabetes mellitus (T2DM) is much higher in subjects with chronic hepatitis C (CHC) than in the general population, ranging between 13% and 67% according to liver fibrosis stage and time of infection [33-35].

The hypothesis that HCV has a direct and important role in the regulation of glucose metabolism is supported by laboratorial investigations. Kasai D et al. showed that HCV replication can down- regulate the glucose transporter 2 expressions, which located on the surface of the cell, thereby affecting cellular uptake of glucose [36]. Deng L et al. found that HCV up-regulated hepatic glucose production via NS5A-mediated FoxO1-dependent pathway [37]. Recently, more systematic mechanisms underlying disorders of glucose metabolism caused by HCV infection have been observed in many experimental and clinical studies. HCV may directly inhibit the insulin-signaling pathway, with downregulation of glucose transporter 2, promotion of IRS-1 degradation through protein kinase B (Akt)/mammalian target of rapamycin (mTOR) activation, and suppression of phosphorylation of tyrosine on IRS-1. Moreover, HCV impairs phosphorylation of Akt, leading to a reduction in insulin stimulation [32].

The complex association between HCV infection and dysregulation of lipid metabolism has also been observed in recent years. Numerous studies have shown that HCV is highly dependent on the host's lipid metabolism to create an environment more suitable for its replication. HCV associates with lipoproteins to form a structure called lipoviral particle (LPV), released by hepatocytes [38-40], which in turn facilitates HCV evading from host immune responses and infecting new cells [40]. Lipid virions are very similar to very low-density lipoproteins (VLDL), not only by the apolipoprotein content, but also by the lipid composition and particle density [38-41]. Likewise, VLDL secretion pathway of infected cell is redirected by the virus especially for virion maturation/secretion, and the low-density lipoprotein (LDL) receptor is an essential component employed by HCV during cell adsorption and entry [42]. Therefore, in HCV-infected patients, lipid metabolism is often observed to be down-regulated, which is characterized by decreased serum lipoprotein and total cholesterol, and substantial lipid accumulation [39].

Because of the serious metabolic disorder and consecutive related diseases due to HCV infection, the question of whether the success of DAA treatment can repair the metabolic damage arises. Until now, progressing studies have shown that DAA treatment has some beneficial impacts on both glucose metabolism and lipid metabolism.

Several studies indicated that DAA therapies indeed change the state of glucose metabolism in patients with the clearance of HCV. However, there is a certain contradiction in the results of these studies. A retrospective study carried out on 300 patients suggested that blood glucose levels significantly decreased in subjects with diabetes who achieved SVR. And most of the observed variation occurred early in time and in temporal concert with HCV clearance. Furthermore, the metabolic improvement was persistent with a reduction of average fasting glucose level for >1 year after the end of therapy [32].Consistent with the conclusion, there are some studies that reported similar results; a reduction of fasting glucose levels after HCV clearance had no obvious association with HCV genotype, body mass index (BMI) of patients and the DAA regimen used [43, 44].

In contrast, Philip Weidner et al. discovered that SVR is closely associated with the decline of fasting blood glucose levels in patients, and this decline will continue until 24 weeks after the completion of the treatment. However, the fasting blood glucose concentration will return to baseline level after 48 weeks [45]. In addition, a 5-year's follow-up study by Jia Li et al. carried out on 384 HCV patients with T2D revealed that there was no significant difference in the concentration of HbA1c between untreated patients and those with treatment failure, whereas the variation of concentration of HbA1c in patients with successful DAA treatment experienced three stages: average HbA1c started off at roughly 7.7 and decreased significantly over time (P<0.001); then the concentration of HbA1c began to rise slowly (P=0.003); finally, HbA1c stabilized at an average level of 7.9 (p-value for the slope=0.337) [46].

The contradictory of these results may be explained by the length of follow-up after the end of treatment as well as different characteristics of subjects employed. In summary, a conclusion can be drawn that DAA have a positive impact on glucose metabolism damage early in time after the completion of DAA treatment, but this beneficial effect will gradually disappear as the follow-up time is extended.

With respect to lipid metabolism impairment in patients, unlike the short-term beneficial impact of DAA therapies on glucose metabolism, numerous studies have supported the hypothesis that HCV clearance after therapy is associated with a significant improvement in the lipid profile. A study by Gilmar de Souza Lacerda et al. found that the level of serum total cholesterol (P<0.0001), low density lipid protein- C (P<0.0001), VLDL-C (P=0.0003) and triglyceride (P=0.0003) were greatly elevated in patients who had acquired SVR at the end of treatment and 1 year after the end of treatment, while HDL-C levels in serum were not significantly changed, comparing with the baseline level [47]. Similar results were observed in the study by Matt Driedger et al. They found out that post-treatment levels of cholesterol (n=36) and triglycerides (n=28) were also evaluated. Overall, a numerical increase was observed from baseline in both total cholesterol (P=0.06) and triglyceride levels (P=0.40). And patients with diabetes were noted to have an elevation in cholesterol after treatment (P=0.05 by Wilcoxon test; n=10), but no significant change in triglycerides (P=0.50 by Wilcoxon test; n=7) [48].In line with these results, several clinical studies provided strong evidence that lipoprotein levels and liver lipid accumulation were inclined to normalize after the initiation of combination therapy including sofosbuvir/ribavirin, sofosbuvir/ledipasvir, asunaprevir/daclatasvir and grazoprevir/elbasvir. These modifications appear to be associated with significant improvement of steatosis and atherogenesis [49-53].

Accordingly, these results support the conclusion that lipid metabolism damage caused by HCV can be completely reversed after DAA successfully removes the virus, which can improve the liver lipid degeneration and atherosclerosis [32].

To conclude, the question of whether DAA treatment can exert a beneficial impact on the metabolic impairment can be answered to date: DAA indeed can recover lipid metabolism damage, but only a short-term positive outcome on glucose metabolism damage.

 Figure 1 

Hepatitis C virus (HCV)-associated glucose and lipid metabolic changes [32]. GLUT2, glucose transporter 2; INS, insulin; IRS, insulin receptor substrate; mTOR, mammalian target of rapamycin; SOCS3, suppressor of cytokine-signalling protein; AKT, protein kinase B (Akt); FoxO1,forkhead box protein O1, transcription factor; PEPCK, phosphoenolpyruvate carboxykinase; G6Pase, glucose-6-phosphatase; SREBP, sterol regulatory element-binding protein; SRE, sterol regulatory element; PPAR, peroxisome proliferator-activated receptor; PPRE, PPAR response element; NS5A, HCV non-structural protein 5A;VLDL, very-low-density lipoprotein cholesterol; ApoB, apolipoprotein B; TG, triglycerides; FA, fatty acid.

Int J Med Sci Image (Click on the image to enlarge.)

Rehabilitation of Immune Damage

A great deal of studies have shown that HCV infection will induce the up-regulation of many genes involved in innate immunity characterized by up-regulation of interferon-stimulated genes (ISGs) expression [54-56], elevated levels of interferon- sensitive cytokines and chemokines [53, 57-60]. More importantly, the chronic activation of the innate immune response and the consequent activation of hepatic stellate cells are the initiators of hepatitis and cirrhosis [61]. HCV may interact with immunity response through multiple mechanisms. It is well known that HCV RNA can be recognized by the Toll-like receptor 3 or the RIG-I helicase-mediated pathway in the cytoplasm, resulting in transcriptional activation of type 1 interferon. And type 1 interferon can activate the JAK-STAT signal pathway, which subsequently precedes the transcription of ISGs that have antiviral effects [62]. Simultaneously, the increased type 1 IFN can also trigger natural killer cells and make it a polarized phenotype, elevated cytotoxicity, and down-regulation of the pro- apoptotic factors TRAIL and cytokines [63].

Moreover, in addition to changing innate immune response, HCV infection also leads to changes in specific immune response. In patients with chronic HCV infection, T cell responses can only be detected at low levels [64]. This is because sustained antigenic stimulation results in up-regulation of T cell depletion markers, such as programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), T-cell immunoglobulin and mucin-domain containing-3 (Tim-3),cytotoxic T lymphocyte antigen 4(CTLA-4),CD160, B- and T-lymphocyte attenuator [65], which indicates the increasing population of phenotype of depleted T cells. Ultimately, the outcome of changes in the expression of these genes is that, partial or total loss of antiviral function and proliferation of T cells. This result can also be verified in animal models that the population of depleted T cell was found to be attenuated after IFN signaling [66].

Unlike interferon-based treatments, DAA treatment acts precisely on some critical steps of HCV replication, thereby preventing HCV replication. It plays a role in the treatment of CHC less dependent on the host's immune function. Hence, many researchers speculate that the dysfunction of CHC patient's immune system may be recovered partially or completely with the DAA clearing HCV.

To date, there is an extensive body of evidence that innate immune and specific immune response damage can be recovered in subjects with HCV clearance by DAA treatment, and this restoration presents long-term effect. According to a study of Matthew A. Burchill et al., interferon-free DAA treatment can trigger a global rearrangement of innate immune signals and inflammatory pathways in patients with chronic hepatitis C. They observed an obvious reduction in the transcription of the cytokine IL1β involved in innate immune activation, hepatic inflammation, and fibrosis parallel with the deregulated phosphorylation levels of NF-ΚB protein that is associated with the activation of downstream signaling and innate immune. In addition, the level of C-X-C motif chemokine (CXCL)-10 and CXCL 11 also decline rapidly during treatment acting as chemokines, which can guide the innate immune cells to accumulate in the inflammatory part. This phenomenon indicates a reduction of the levels of HCV RNA in peripheral blood and an amelioration of liver inflammation. In addition, the expression of innate immune signaling related molecules such as retinoic acid induced gene I (RIG-I), Signal transducing activator of transcription 1 (STAT1), and interferon regulatory factor 7 (IRF7) is down- regulated, therefore, the rapid dampening of innate immune activation following rapid viral clearance with IFN-free DAA therapy is independent of the treatment regimen utilized[67, 68].

In fact, the repair of immune dysfunction stemmed from DAA therapies changes the expression of major immune-related molecules, and the number and phenotype of innate immune cells and specific immune cells are also changed. Eric G. Meissner et al. found out that the concentration of lymphocyte in peripheral blood was increased dramatically during the first two weeks of DAA treatment, but this upregulation did not last for the entire treatment process. The increase of the population of T lymphocytes in peripheral blood can be reflected as a combined effect of reduced intrahepatic migration of lymphocytes due to changes in chemotaxis and potential outflow of intrahepatic lymphocytes [69]. The most obvious visual variation over the course of treatment was a reduction in CD8 signal in the parenchymal and nonparenchymal regions of liver, which was observed in all patients who received DAA treatment, as well as some patients with treatment failure. Hence, this result indicates that the frequencies of CD8+T cells may have no correlation with the treatment outcome. Similarly, in clinical trials, Cody Orr et al. speculated that the decrease of population of CD8+ T cells may be due to a decrease in HCV concentration, contributing to an intrahepatic cellular response to reduction in viral burden. In addition, the population of CD4+T cells also declined in the non-parenchymal region of liver, while the significant variation of frequencies of Kupffer cells associated with inflammation was not observed [70].

Furthermore, studies by Shikha Shrivastava et al. showed that the expression of depleted T cell markers was reduced during DAA treatment, and the proportion of exhausted phenotypes T cell was obviously declined ,but the proportion of HCV-specific CD8+ cells is correspondingly heightened. Because the exhausted T cells partially or completely lose their ability to secrete antiviral cytokines such as IFN-α, IFN-γ, and IL-2. However, after successful treatment, compared with baseline levels, the expression levels of these cytokines are increased in T cells, which mean a recovery to some extent in HCV-specific immune response. Thence, amplification in HCV-specific CD8+ T cell responses is a direct result of decreased expression of T cell depletion markers [71]. In addition, 4 years after HCV clearance by DAA, a steady growth in the number of regulatory T cells was observed in patients, indicating that DAA has a sustained effect on immune function in the liver for a long period of time after the clearance of HCV [72]. Interestingly, however, the memory phenotype of CD4 T cells and CD8 T cells did not make changes during the course of treatment.

Additionally, it is well documented that patients co-infected with HIV and HCV have higher levels of immune activation and impaired antigen-specific responses compared to patients mono-infected with HCV[65].It is important to assess the impact of DAA therapies on recovery of immune dysfunction in subjects with HIV/HCV co-infection. Several small studies have demonstrated improvement in liver ISG expression, restoration of type I IFN signaling, and natural killer and T cell function following IFN-free DAA therapy in the setting of chronic infection [73-75].Furthermore, DAA combination therapies in patients co-infected with HIV/HCV resulted in similar restoration of the T-cell impairments and perturbations associated with HIV/HCV coinfection to an extent. However, the effect of improvement of immune response in patients with DAA treatment is different, as the result of Shikha Shrivastava et al. shown that patients co-infection with HIV/HCV lead to greater restoration of the immunologic outcomes to an extent that was greater in three-drug combination therapies than that observed in either two-drug regimens[65].Consequently, a conclusion can be drawn that successful DAA treatment indeed restore the dysfunction of immunity system to some extent in patients with HIV/HCV co-infection.

Thus, available results all favored the conclusion that immune impairment due to HCV infection and HCV/HIV co-infection after the end of successful DAA treatment, which is characterized by the reduction in proportion of exhausted T cells and enhancement of virus-specific T cells response, and remarkable amelioration of liver inflammation, can be observed in the responders. Furthermore, lacking continuous IFN stimulation in the liver after clearance of the virus with DAA will likely also have a significantly beneficial effect on intrahepatic immune responses.

 Figure 2 

Change of immune cell function after HCV clearance by successful DAA treatment[76].

Int J Med Sci Image (Click on the image to enlarge.)

Drug Resistance

Although DAA presents a high SVR for HCV-infected patients with the six major genotypes (HCV GT3 patients have a slightly lower SVR), it still confronts with the challenge of drug resistance, especially resistance-associated substitutions (RASs), which is the main reason of treatment failure. Drug resistance is an intrinsic and unavoidable problem in antiviral therapy because of the high adaptability of HCV and the failure to maintain a high pressure of inhibition [77], and the emergence of RASs will reduce the cure rate of the drug.

It is well known that resistance mutations are favored by the lack of efficient proof-reading activity of HCV RNA-dependent RNA polymerase, which elevated to be between 103 and 105 per copied base pair, as well as the high rate of viral replication (up to 1012 particles produced per day), leading to one mutation for every genome copied. As a consequence, HCV exists as a quasi-species population: a complex mixture of genetically distinct but closely related viral populations that constitutes a reservoir for the emergence of resistant strains [78]. Not surprisingly, resistance emerges when replication occurs in the presence of drug-selection pressure. The probability of a mutation associated with drug resistance being selected out during therapy relies on the potency of that drug. Undoubtedly, in addition to the RASs emerging after virological failure, there are some resistance mutations that occur naturally before treatment, which both have a negative effect on cure rate, and may eventually resulting in treatment failure. In general, there are many factors associated with the occurrence of RASs, including therapy regimen, genotype and subtype of HCV and geographical distribution.

Encouraging clinical and retrospective study have shown that the prevalence of RASs in the gene regions of three non-structural proteins of HCV is not the same, and this may be due to their different roles in HCV life cycle, which determines the resistance barriers of the three non-structural proteins of HCV are different (the genetic barrier to drug resistance defines as the types and number of mutations needed to develop the resistant phenotype [79]). Therefore, there is a difference in prevalence of the resistance associated mutations that selected from DAA administration among these three non-structural proteins.

RASs at positions 53, 80, 122, 155 and 168 within the NS3 protease region are often associated with virological failure with PIs [80]. Mechanically, emergence of RASs to reducing the cure rate of PIs is mainly due to the changes of the conformation of viral proteases, which makes it more difficult for PIs to stably bind to drug targets, ultimately resulting in a decrease in SVR. For example, when simeprevir (TMC435) is used for the treatment of HCV infection, the conformation of R155 is good for facilitating its interaction with the simeprevir crystal structure. Moreover, a salt bridge network structure formed between Q80, R155 and D168 is vital to stabilizing this interaction. Nevertheless, the mutation of R155K caused the salt bridge structure to fail to form, which reduces the stability of interactions of drug and protease. Thus, mutations in R155K, D168A, and Q80K ultimately contribute to the effect of simeprevir escaped by NS3 [81].

NS5A inhibitors are an indispensable component of all first-line DAA regimens as they are the class of HCV drugs where resistance is most clinically relevant. With respect to NS5A inhibitors, it works mainly by binding to domain 1 of the NS5A dimer, but the specific mechanism of inhibition still remains unclear. The RAS of M/L28T/V, Q/L30E/H/R/S, L31M/V, H58D and Y93C/H/N are the most frequently in NS5A when the patients are treated with NS5A inhibitors [82].Considering the above, RASs of M28A/G/T/V are most frequently in GT1a prior to drug exposure (4-8% M28T/V), and Y93 variants (Y93C/H/N) of NS5A RASs have the most clinical importance (< 7×),which are found most frequently in GT1b (10%) and GT3 (8-10%) but appear rarely in GT1a (< 1%). However, the Variants at position 93 in GT1a can confers very high level resistance to all class NS5A inhibitors except for pibrentasvir (PIB) (< 7×) [83, 84]. The occurrence of RASs leads to a decrease in the affinity of the NS5A inhibitor and NS5A, which finally compromises its effectiveness.

The spectrum of mutations associated with NS5B inhibitors is likewise broad. Similar to HIV therapy, HCV polymerase inhibitors also can be subdivided into two types: nucleosides (NIs) and non-nucleoside inhibitors (NNIs). Because all NISs target the highly conserved active sites of polymerases, these inhibitors tend to be pan-generic [85]. In the course of treatment with NIs, the most important compound from this class is sofosbuvir. In pre-clinical assessment of sofosbuvir, a serine to threonine substitution at position 282 of polymerase (S282T) conferred a 10-fold resistance against sofosbuvir [86]. The in vitro analysis of the S282T variant showed that the affinity of the mutated polymerase for nucleoside analogs was reduced, and this substitution also resulted in a significant loss of replication fitness [87]. Non- nucleoside inhibitors bind to allosteric binding sites outside the polymerase active site, and their resistance barriers are lower compare with NIs. Dasabuvir is currently the only approved non-nucleoside inhibitor. For dasabuvir, the common RASs in NS5B are M414T and S556G [88], or A421V and P495L/S [89].

In addition to these common resistance mutations, several prevalence studies have demonstrated that there are still some RASs pre-existing prior to the treatment within the viral population of an infected patient. Although not as common as the RASs merging under drug selective pressure, baseline resistance may also affect the outcome of DAA therapy.

As epidemiological studies have shown that Q80K RAS in NS3 is associated with significantly lower SVR rates for treatment with SMV + peg-IFN-α + RBV[90], existing as a natural polymorphism mainly in HCV GT1a (20-52%) [91]. In particular, the presence of Q80K is an especially challenge in G1a infected patients with cirrhotic, as they treated with SMV + SOF, lower SVR rates of 74% were observed in the presence of Q80K versus 92% in the absence of Q80K [92]. Therefore, monitoring of Q80K before treatment is recommended in all subjects with HCV GT1a infected, especially treatment with SMV + peg-IFN-α + RBV, while for therapy regimen of SMV + SOF, baseline resistance testing of Q80K is needed only for cirrhotic patients [93].

Variants at positions 31, 54 and 93 are most common in NS5A, including L31M, Q54H and Y93H [94]. For the combination regimen of ASV + DCV, the NS5A variant Y93H was pre-existed in half of the G1b infected patients who went through treatment failure. In contrary to this result, in a UNITY-1 study, despite the higher frequency of NS5A RASs was observed prior to treatment in GT1b compared to GT1a infected patients (16% vs 11%), all subjects with GT1b infection achieved SVR in contrast to only 74% for GT1a [95, 96].Nevertheless, a recent study showed an exciting result that the impact of baseline NS5A RASs on outcome of treatment can be significantly reduced or even completely removed when patients go through a longer duration of treatment with SOF + LDV and addition of RBV[96]. Furthermore, pre-existing RASs in NS5A appeared to have little effect on the outcome of treatment regimen with SOF + VEL, in spite of a high frequency of such variants, 97-100% subjects with baseline resistance in NS5A achieved SVR [97, 98].

Variant L159F in NS5B was detected in 1% of the subjects with GT1 infection and was only observed to have a direct association with accumulated virological failure when patients were treated with SOF + RBV for short durations [99]. Unlike low prevalence and limited effect of L159F in GT1, 34% prevalence of RAV L159F was observed in GT1b and was significantly associated with dropped SVR rates of 25% as opposed to 65% in patients without this variant [100]. In general, a low prevalence of pre-existing RASs was detected in nucleoside inhibitor based regimens [101].

 Table 1 

Cross-resistance pattern of clinically used NS3, NS5A, and NS5b inhibitors (2-fold to>100-fold change resistance)[78].

CategoryNameResistance-associated substitutions
NS3/4 protease inhibitors (PIs)asunaprevir, simeprevir, paritaprevir, grazoprevirF53S, Q80K/R, S122R, R155K, A156T/V, D168 any
NS5A inhibitorsdaclatasvir, ledipasvir, ombitasvir, elbasvir, PibrentasvirM28A/G/T, Q30E/H/R, L31F/M/V, P32L/S, H58D, Y93H
NS5B inhibitorssofosbuvir, dasabuvirC316N

The prevalence of RASs is different among the major genotypes and subtypes of HCV, and it may due to various resistance barriers of them. For example, the most frequent RAS is Y93H in subjects with HCV GT3 and GT1b infection, but rarely observed in patients with HCV GT1a infection [78]. In addition, a protease inhibitor-related R155K-resistant mutation in the NS3 protein requires only one nucleotide change (AGG to AAG) in GT1a HCV infected patients as opposed to the occurrence of R155K RAS requires two nucleotide changes (CGG to AAG) in HCV GT1b infected subjects who initiated therapy with a protease inhibitor. As a result, variant at position 155 is lowering prevalent in HCV G1b infected subjects compared to the G1a infected subjects due to higher resistance barrier [78].

Therefore, it remains necessary to detect the HCV genotype and subtype of a patient. Because a correct HCV genotype/subtype determinate by baseline HCV sequencing can provide critical virological information for the detection of genetic variants that have a potential impact on therapy response, which can guide the selection of the optimal antiviral regimen for patients and decrease frequency of treatment failure.

In addition, encouraging epidemiological studies have demonstrated that the prevalence of RAS is also related to geographical distribution, resulting in some of more frequent mutations in some places. Statistically, the overall prevalence of Q80K is 7.5%, decomposed into19.8% in GT1a, 0.5% in GT1b, and 18.2% in other or unknown GT1 subtypes [102]. Furthermore, the prevalence of Q80K among GT1 patients may be geographically various: the prevalence of Q80K was 34% in a North American G1 population and reached more than 40% in subjects who infected HCV GT1.In Europe, Q80K prevalence in GT1 ranged from 0% in Bulgaria to 18.2% in the UK. But the prevalence was various from country to country owing to different Q80K prevalence and ratios of G1a/G1b within the G1a genotype [102].

In summary, the drug resistance of DAA is associated with a variety of factors, and RASs can be detected in all patients with treatment failure. Thus, the detection of RASs is critical for the success of treatment, including the RASs naturally occurring and selected out during therapy. Until now, the detection of drug resistance mainly relies on Sanger automated sequencing and second-generation sequencing (NGS), and NGS is an emerging technology with great potential in data analysis and data integrity [78]. Of note, international guidelines recommend that RAS present in >15% of sequences are believed clinically significant and should be taken into serious consideration in the selection of treatment regimen [102, 103].Conversely, in a RAS study based on massively parallel, they reported that presence of baseline RASs even much less than 15% of HCV sequences is also associated with treatment failure in two HCV G1a-infected patients treated with ledipasvir (LED)+ sofosbuvir (SOF) [67, 104-106].

Thus, the drug resistance of DAA is a complex and unavoidable problem, which may result in bad response to antiviral therapy and relapse in HCV infected patients. To date, with the aim of decreasing frequency of RASs, it is useful and common to select different classes DAAs for combination treatment. And a correct determination of HCV genotype and subtype and detection of pre-existing RASs in sequence remains important for guiding selection of most appropriate antiviral regimen.


The combination, oral DAA (±RBV) therapies have become the clinical treatment of choice, which has revolutionized cure rate for patients with HCV infection. In addition to the excellent antiviral effect that more than 91% SVR can be achieved in patients, there are some unexpected effects of recovery in liver dysfunction, metabolic disorder and immune function damage in patients with clearance of HCV compared to IFN-based therapy. However, presence of baseline resistance and RASs occurring during antiviral treatment is critical and notable a challenge, which can be observed in all patients with treatment failure. Therefore, with the aim of reduction of frequency in RASs and non-responders, selection of DAA therapies should be taken with many factors into consideration, including correct determination of HCV genotype and subtype and detection of RAS in sequence. Thus, the exploitation of antiviral drugs suitable for the all main HCV genotypes, to minimize the incidence of resistance mutations in order to further improve the sustained viral response, remains a focus of future research and with a great pool of knowledge based on profound researches, more effective therapies are hoped to emerge.


This work was supported by the Natural Science Foundation of Hunan province (Grant No. 2018JJ2554).

Competing Interests

The authors have declared that no competing interest exists.


1. Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161-76

2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333-42

3. Li G, De Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017;142:83-122

4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65

5. Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme AM, Rockstroh JK. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Rev Med Virol. 2016;26:408-34

6. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511

7. Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J. et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis. 2013;57:221-9

8. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P. et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727-33

9. Amaddeo G, Nguyen CT, Maille P, Mule S, Luciani A, Machou C. et al. Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy. Liver Int. 2020;40:74-82

10. Aunins TR, Marsh KA, Subramanya G, Uprichard SL, Perelson AS, Chatterjee A. Intracellular Hepatitis C Virus Modeling Predicts Infection Dynamics and Viral Protein Mechanisms. J Virol. 2018;92:e02098-17

11. Bukh J. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. J Hepatol. 2016;65:S2-S21

12. Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection: Host(-)Virus Interaction and Mechanisms of Viral Persistence. Cells. 2019;8:376

13. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr. et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015;149:649-59

14. Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E. et al. Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals. Eur J Clin Invest. 2019;49:e13056

15. Flisiak R, Janczewska E, Lucejko M, Karpinska E, Zarebska-Michaluk D, Nazzal K. et al. Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir+/-dasabuvir+/-ribavirin in the AMBER, real-world experience study. J Viral Hepat. 2018;25:1298-305

16. Gentile I, Scotto R, Coppola C, Staiano L, Amoruso DC, De Simone T. et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). Hepatol Int. 2019;13:66-74

17. Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM. et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015;373:2618-28

18. Kozbial K, Moser S, Al-Zoairy R, Schwarzer R, Datz C, Stauber R. et al. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment. Liver Int. 2018;38:1028-35

19. Lleo A, Aglitti A, Aghemo A, Maisonneuve P, Bruno S, Persico M. et al. Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Dig Liver Dis. 2019;51:310-7

20. Pokora A, Kiciak S, Tomasiewicz K. Assessing the consistency of liver fibrosis results obtained through biopsy and transient elastography in patients suffering from chronic hepatitis C. Clin Exp Hepatol. 2016;2:109-11

21. Kramer JR, Giordano TP, El-Serag HB. Effect of human immunodeficiency virus and antiretrovirals on outcomes of hepatitis C: a systematic review from an epidemiologic perspective. Clin Gastroenterol Hepatol. 2007;5:1321-8 e7

22. Marine-Barjoan E, Saint-Paul MC, Pradier C, Chaillou S, Anty R, Michiels JF. et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS. 2004;18:2163-70

23. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M. et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology. 2001;34:1193-9

24. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A. et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infection patients. The Multivirc Group. Hepatology. 1999;30:1054-8

25. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M. et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319-27

26. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C. et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223-31

27. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG. et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313:1232-9

28. d'Arminio Monforte A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, Lo Caputo S, Castagna A. et al. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PloS one. 2017;12:e0177402

29. Piroth L, Wittkop L, Lacombe K, Rosenthal E, Gilbert C, Miailhes P. et al. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. J Hepatol. 2017;67:23-31

30. Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K. et al. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Co-infection Individuals: Results From the German Hepatitis C Cohort (GECCO-01). Clin Infect Dis. 2016;63:1320-4

31. Macias J, Granados R, Tellez F, Merino D, Perez M, Morano LE. et al. Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection. J Viral Hepat. 2019;26:16-24

32. Lanini S, Scognamiglio P, Pisapia R, Minosse C, Agresta A, Ippolito G. Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy. Int J Antimicrob Agents. 2019;53:559-63

33. Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S. et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102:570-6

34. Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne). 2015;6:134

35. Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E. et al. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology. 2012;56:1681-7

36. Kasai D, Adachi T, Deng L, Nagano-Fujii M, Sada K, Ikeda M. et al. HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters. J Hepatol. 2009;50:883-94

37. Deng L, Shoji I, Ogawa W, Kaneda S, Soga T, Jiang DP. et al. Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway. J Virol. 2011;85:8556-68

38. Aizawa Y, Seki N, Nagano T, Abe H. Chronic hepatitis C virus infection and lipoprotein metabolism. World journal of gastroenterology. 2015;21:10299-313

39. Felmlee DJ, Hafirassou ML, Lefevre M, Baumert TF, Schuster C. Hepatitis C virus, cholesterol and lipoproteins-impact for the viral life cycle and pathogenesis of liver disease. Viruses. 2013;5:1292-324

40. Fukuhara T, Ono C, Puig-Basagoiti F, Matsuura Y. Roles of Lipoproteins and Apolipoproteins in Particle Formation of Hepatitis C Virus. Trends Microbiol. 2015;23:618-29

41. Crouchet E, Baumert TF, Schuster C. Hepatitis C virus-apolipoprotein interactions: molecular mechanisms and clinical impact. Expert Rev Proteomics. 2017;14:593-606

42. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab. 2010;21:33-40

43. Abdel Alem S, Elsharkawy A, Fouad R, Adel E, Abdellatif Z, Musa S. et al. Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience. J Med Virol. 2017;89:2181-7

44. Pavone P, Tieghi T, d'Ettorre G, Lichtner M, Marocco R, Mezzaroma I. et al. Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. Clin Microbiol Infect. 2016;22:462 e1-3

45. Weidner P, Boettche D, Zimmerer T, Burgermeister E, Teufel A, Ebert MPA. et al. Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C. J Gastrointestin Liver Dis. 2018;27:281-9

46. Li J, Gordon SC, Rupp LB, Zhang T, Trudeau S, Holmberg SD. et al. Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis C. Liver Int. 2019;39:1027-32

47. Lacerda GS, Medeiros T, Rosario NFD, Peralta RHS, Cabral-Castro MJ, Esberard EBC. et al. Exploring lipid and apolipoprotein levels in chronic hepatitis C patients according to their response to antiviral treatment. Clin Biochem. 2018;60:17-23

48. Driedger M, Galanakis C, Doyle MA, Cooper CL. Direct-acting antiviral hepatitis C virus treatment perturbation of the metabolic milieu. Eur J Gastroenterol Hepatol. 2019;31:260-6

49. Meissner EG, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D. et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015;61:790-801

50. Sun HY, Cheng PN, Tseng CY, Tsai WJ, Chiu YC, Young KC. Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection. Gut. 2018;67:1342-50

51. Younossi ZM, Elsheikh E, Stepanova M, Gerber L, Nader F, Stamm LM. et al. Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels. J Viral Hepat. 2015;22:977-82

52. Chida T, Kawata K, Ohta K, Matsunaga E, Ito J, Shimoyama S. et al. Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b. Gut Liver. 2018;12:201-7

53. Peng L, Yuan XQ, Liu ZY, Li WL, Zhang CY, Zhang YQ. et al. High lncRNA H19 expression as prognostic indicator: data mining in female cancers and polling analysis in non-female cancers. Oncotarget. 2017;8:1655-67

54. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y. et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010;139:499-509

55. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD. et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010;52:1888-96

56. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W. et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:7034-9

57. Han ZQ, Huang T, Deng YZ, Zhu GZ. Expression profile and kinetics of cytokines and chemokines in patients with chronic hepatitis C. International journal of clinical and experimental medicine. 2015;8:17995-8003

58. Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clement S. et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther. 2011;33:1162-72

59. Lagging M, Askarieh G, Negro F, Bibert S, Soderholm J, Westin J. et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PloS one. 2011;6:e17232

60. Jablonska J, Pawlowski T, Laskus T, Zalewska M, Inglot M, Osowska S. et al. Erratum to: 'The correlation between pretreatment cytokine expression patterns in peripheral blood mononuclear cells with chronic hepatitis c outcome'. BMC Infect Dis. 2016;16:104

61. Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14:397-411

62. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R. et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature. 2005;437:1167-72

63. Golden-Mason L, Rosen HR. Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunol Rev. 2013;255:68-81

64. Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut. 2012;61:1226-34

65. Shrivastava S, Bhatta M, Ward H, Romani S, Lee R, Rosenthal E. et al. Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Co-infection With Human Immunodeficiency Virus and Hepatitis C Virus. Hepatol Commun. 2018;2:1451-66

66. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M. et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science. 2013;340:207-11

67. Peng L, Yuan XQ, Zhang CY, Ye F, Zhou HF, Li WL. et al. High TGF-beta1 expression predicts poor disease prognosis in hepatocellular carcinoma patients. Oncotarget. 2017;8:34387-97

68. Burchill MA, Roby JA, Crochet N, Wind-Rotolo M, Stone AE, Edwards MG. et al. Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy. PloS one. 2017;12:e0186213

69. Meissner EG, Kohli A, Higgins J, Lee YJ, Prokunina O, Wu D. et al. Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection. Hepatol Commun. 2017;1:586-94

70. Orr C, Aartun J, Masur H, Kottilil S, Meissner EG. Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. J Viral Hepat. 2019;26:323-8

71. Shrivastava S, Wilson E, Poonia B, Tang L, Osinusi A, Kohli A. et al. Augmentation of hepatitis C virus-specific immunity and sustained virologic response. J Viral Hepat. 2017;24:742-9

72. Esposito I, Marciano S, Haddad L, Galdame O, Franco A, Gadano A. et al. Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection. Viruses. 2019;11:3

73. Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D. et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. The Journal of clinical investigation. 2014;124:3352-63

74. Martin B, Hennecke N, Lohmann V, Kayser A, Neumann-Haefelin C, Kukolj G. et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol. 2014;61:538-43

75. Serti E, Chepa-Lotrea X, Kim YJ, Keane M, Fryzek N, Liang TJ. et al. Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function. Gastroenterology. 2015;149:190-200 e2

76. Werner JM, Adenugba A, Protzer U. Immune Reconstitution After HCV Clearance With Direct Antiviral Agents: Potential Consequences for Patients With HCC?. Transplantation. 2017;101:904-9

77. Pawlotsky JM. Hepatitis C virus population dynamics during infection. Curr Top Microbiol Immunol. 2006;299:261-84

78. Bagaglio S, Uberti-Foppa C, Morsica G. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs. 2017;77:1043-55

79. Ploss A, Dubuisson J. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut. 2012;61(Suppl 1):i25-35

80. Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J. et al. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. Gastroenterology. 2016;151:651-9 e1

81. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol. 2013;3:514-20

82. Wyles DL. Resistance to DAAs: When to Look and When It Matters. Curr HIV/AIDS Rep. 2017;14:229-37

83. Wyles D, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Martin R, Afdhal NH. et al. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. J Hepatol. 2017;66:703-10

84. Ng T, Lu L, Reisch T, Krishnan P, Schnell G, Tripathi R. et al. Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypes. Journal of Hepatology. 2017;66:S324-S

85. Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R. et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59:1666-74

86. Martel-Laferriere V. ABT-450/r-ombitasvir and dasabuvir with ribavirin eliminates viraemia in most patients with HCV infection with cirrhosis. Evid Based Med. 2015;20:6

87. Gotte M. The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance. Curr Opin Virol. 2012;2:644-50

88. Sims KD, Lemm J, Eley T, Liu M, Berglind A, Sherman D. et al. Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection. Antimicrob Agents Chemother. 2014;58:3496-503

89. Sarrazin C, Lathouwers E, Peeters M, Daems B, Buelens A, Witek J. et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res. 2015;116:10-6

90. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV. et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403-13

91. Cuypers L, Li G, Libin P, Piampongsant S, Vandamme AM, Theys K. Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. Viruses. 2015;7:5018-39

92. Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R. et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology. 2016;64:360-9

93. Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932-54

94. Watabe T, Korenaga M, Sugiyama M, Kumagai E, Ueyama M, Aoki Y. et al. Distribution of pre-existing NS5A/NS5B resistance associated variants in genotype 1b patients with hepatitis C virus and response to direct acting antivirals. Hepatology. 2015;62:1083a-a

95. Reddy KR, Beavers KL, Gordon S, Harrison S, Reau N, Yozviak J. et al. Effect of Baseline Factors on Response to the Fixed-Dose Combination of Daclatasvir (Dcv), Asunaprevir (Asv) and Beclabuvir (Bcv) in Non-Cirrhotic Patients with Hcv Genotype 1 Infection. Journal of Hepatology. 2015;62:S676-S7

96. Fourati S, Roudot-Thoraval F, Chevaliez S, Scoazec G, Soulier A, Varaut A. et al. Patients with HCV GT 1/4 infection and compensated cirrhosis, without baseline NS5A RASs, could be treated with SOF+NS5A inhibitor for 12 weeks without RBV. Hepatology. 2016;64:945a-6a

97. Lawitz E, Flamm S, Yang JC, Pang PS, Zhu Y, Svarovskaia E. et al. Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir- Based Regimens with Ledipasvir/Sofosbuvir for 24 Weeks. Journal of Hepatology. 2015;62:S192-S

98. Charlton M, Manns M, Dvory-Sobol H, Svarovskaia E, Doehle B, Arterburn S. et al. Resistance Analyses for Ledipasvir/Sofosbuvir Containing Regimens in Patients Infected with Chronic Hcvwhohave Advanced Liver Disease or Are Post Liver Transplant (Solar-1 & 2 Studies). Journal of Hepatology. 2016;64:S186-S

99. Kwo PY, Wyles DL, Wang S, Poordad F, Gane E, Maliakkal B. et al. 100% Svr4 with Abt-493 and Abt-530 with or without Ribavirin in Treatment-Naive HCV Genotype 3-Infected Patients with Cirrhosis. Journal of Hepatology. 2016;64:S208-S

100. Muir AJ, Strasser S, Wang S, Shafran S, Bonacini M, Kwo P. et al. High Svr Rates with Abt-493+Abt-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection. Journal of Hepatology. 2016;64:S186-S

101. Chen ZW, Li H, Ren H, Hu P. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. Sci Rep. 2016;6:20310

102. Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R. et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. J Hepatol. 2017;66:910-8

103. Pawlotsky JM. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology. 2016;151:70-86

104. Perales C, Chen Q, Soria ME, Gregori J, Garcia-Cehic D, Nieto-Aponte L. et al. Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant. Infect Drug Resist. 2018;11:2207-10

105. Zhang C, Peng L, Zhang Y, Liu Z, Li W, Chen S. et al. The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data. Med Oncol. 2017;34:101

106. Ge Y, Zhang C, Xiao S, Liang L, Liao S, Xiang Y. et al. Identification of differentially expressed genes in cervical cancer by bioinformatics analysis. Oncol Lett. 2018;16:2549-58

Author contact

Corresponding address Corresponding author: Shuiping Liu, E-mail:

Received 2019-12-15
Accepted 2020-2-25
Published 2020-3-15